SI9725: MLN2238


In stock


MLN2238 is a proteasome inhibitor. Much like Bortezomib, MLN2238 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.


Purity >99% (HPLC), NMR (conforms)
Quantity 5 mg
Molecular Weight 361.03 Da
Physical State Lyophilized powder
Solubility DMSO (72 mg/mL); ethanol (9 mg/mL)
CAS No. 1072833-77-2
Storage 4°C, (-20°C Long term). The product can be shipped at room temperature.

Additional information



There are no reviews yet.

Be the first to review “SI9725: MLN2238”


  • Inhibition of chymotrypsin-like proteasome catalytic activity.
  • Cellular studies of proteasome inhibition.